COMPASS Pathways plc (NASDAQ:CMPS) Receives $21.83 Average Target Price from Analysts

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the last year is $20.20.

A number of research analysts recently issued reports on CMPS shares. Canaccord Genuity Group dropped their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reissued an "outperform" rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Cantor Fitzgerald restated an "overweight" rating on shares of COMPASS Pathways in a research note on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a "buy" rating and a $11.00 price objective for the company.

COMPASS Pathways Trading Down 6.8 %

Shares of CMPS traded down $0.21 during trading hours on Friday, hitting $2.88. 224,256 shares of the stock were exchanged, compared to its average volume of 753,727. The firm has a market capitalization of $266.90 million, a P/E ratio of -1.31 and a beta of 2.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a fifty-two week low of $2.69 and a fifty-two week high of $10.31. The business has a 50-day moving average of $3.82 and a 200-day moving average of $4.63.

Remove Ads

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, research analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Trading of COMPASS Pathways

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP bought a new position in shares of COMPASS Pathways in the fourth quarter valued at approximately $11,714,000. Altium Capital Management LLC bought a new position in COMPASS Pathways during the 4th quarter valued at $5,384,000. Tang Capital Management LLC bought a new position in COMPASS Pathways during the 4th quarter valued at $3,780,000. Nantahala Capital Management LLC boosted its holdings in COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company's stock worth $3,780,000 after acquiring an additional 800,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of COMPASS Pathways in the 4th quarter worth $2,458,000. 46.19% of the stock is owned by institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.